II. Indications
III. Background
- Watchman Device is placed percutaneously via femoral artery
- Device is inserted into and occludes the left atrial appendage
- Patient continues Anticoagulation for first 45 days after Watchman Device Placement
- Within 45 days, Myocardium grows over the device (after which Anticoagulation is no longer needed)
- Left atrial appendage Occlusion is an alternative to Anticoagulation for Cerebrovascular Accident Prevention
IV. Efficacy
- Compared with Atrial Fibrillation Anticoagulation
- Watchman Device is associated with lower Hemorrhagic Stroke rate
- Watchman Device is associated with lower cardiovascular mortality
- Watchman Device is similar to Atrial Fibrillation Anticoagulation in the Prevention of Ischemic Stroke
- Reduced stroke following cardiac surgery for other reasons (NNT 43 over 4 years)
- References
V. Complications
- Overall complication rate 1 to 8%
- Complications are most typical immediately after placement
- Cardiac Perforation and Cardiac Tamponade
- Typically occurs at time of procedure
- Delayed presentation with slow leak is possible, but rare
- Percicarditis or Myocarditis
- Femoral Artery access site complications
- Inguinal Hematoma
- Arteriovenous Fistula
- Retroperitoneal Bleeding
-
Cerebrovascular Accident
- Transiently increased risk in the first 45 days
- Device Embolization (rare)
VI. Management
- Recurrent Atrial Fibrillation in patient with LAAO and no Anticoagulation
- Follow same guidelines for cardioversion for patients without LAAO
- Presentation <48 hours from Atrial Fibrillation onset
- May cardiovert without TEE and anticoagulate for 4 weeks after cardioversion
- Discuss with general cardiology or electrophysiology
- Presentation >48 hours from Atrial Fibrillation onset
- Anticoagulate and plan for TEE and cardioversion
- References
- Swaminathan, Shoenberger and Haywood (2026) Mailbag, EM:Rap, 3/30/2026
VII. References
- DeMeester and Swaminathan in Herbert (2021) EM:Rap 21(10): 12-3
- [PubMed]